X-linked hypophosphatemic rickets (XLH) is characterized by rickets, disproportionate short stature, impaired renal phosphate reabsorption and vitamin D metabolism. Despite oral phosphate and vitamin D treatment, most children with XLH demonstrate reduced adult height. The main objective of the study is to determine the beneficial effects of recombinant human growth hormone (rhGH) therapy on body proportions after 36 month in these patients. Secondary objective is to monitor side effects of the therapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
University Childrens Hospital, Rostock
Rostock, Mecklenburg-Vorpommern, Germany
change of body proportion and final height
Time frame: within 5 years
side effects of therapy with rhGH
Time frame: within 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.